40
Participants
Start Date
September 30, 2013
Primary Completion Date
August 31, 2015
Study Completion Date
August 31, 2015
Treosulfan
This is a phase II, open-label, nonrandomized, prospective study of a preparative regimen consisting of treosulfan, fludarabine and low-dose total body irradiation (TBI) for children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT).
Children's National Medical Center, Washington D.C.
Medical University of South Carolina, Charleston
All Children's Hospital, St. Petersburg
Children's Hospital of Alabama/UAB, Birmingham
St. Jude's Children's Research Hospital, Memphis
Nationwide Children's Hospital, Columbus
University Hospitals Case Medical Center, Cleveland
Cleveland Clinic, Cleveland
Riley Hospital for Children/Indiana University, Indianapolis
University of Michigan, Ann Arbor
Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee
University of Wisconsin - Madison, Madison
University of Minnesota, Minneapolis
Washington University, St. Louis Children's, St Louis
Children's Mercy Hospital, Kansas City
Methodist Children's Hospital of South Texas, San Antonio
Children's Hospital of Colorado, Aurora
Primary Children's Medical Center - University of Utah, Salt Lake City
Phoenix Children's Hospital, Phoenix
City of Hope, Duarte
OHSU/Doernbecher Children's Hospital, Portland
Fred Hutchinson Cancer Research Center, Seattle
Children's Hospital Los Angeles, Los Angeles
National Marrow Donor Program
OTHER
Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT)
UNKNOWN
Pediatric Blood and Marrow Transplant Consortium
OTHER
St. Baldrick's Foundation
OTHER
medac GmbH
INDUSTRY
Center for International Blood and Marrow Transplant Research
NETWORK